Abstract
Hyperhomocysteinemia is increasingly recognized as an independent risk factor for several cerebral, vascular, ocular, and agerelated disorders. Whether it is a cause or a consequence or a mere marker necessitates further clarification. This review focuses on the pathophysiological aspects of homocysteines involvement in neurodegenerative and neuropsychiatric disorders and complications. The pharmacological agents (antiepileptic drugs, L-DOPA) augment the homocysteine levels, thus, raising concern for physicians. The mechanisms underlying the enhanced homocysteine levels and its related pathophysiological cascades remain poorly understood, inspite of numerous epidemiological and research studies that have been carried out in recent years. This article will review the current understanding of these underlying mechanisms and the research being carried with homocysteine as a core molecule.
Keywords: Homocysteine, homocysteine thiolactone, hyperhomocysteinemia, diagnostic marker, prognostic marker, predictive marker, L-DOPA, HCY, Folic acid, Pyridoxine, Cobalamin, Trimethylglycine, Choline, Melatonin, MK-801
CNS & Neurological Disorders - Drug Targets
Title: Homocysteine in Neurological Disease: A Marker or a Cause?
Volume: 10 Issue: 3
Author(s): Suruchi Khanna, Puneet Kapoor, K. K. Pillai and Divya Vohora
Affiliation:
Keywords: Homocysteine, homocysteine thiolactone, hyperhomocysteinemia, diagnostic marker, prognostic marker, predictive marker, L-DOPA, HCY, Folic acid, Pyridoxine, Cobalamin, Trimethylglycine, Choline, Melatonin, MK-801
Abstract: Hyperhomocysteinemia is increasingly recognized as an independent risk factor for several cerebral, vascular, ocular, and agerelated disorders. Whether it is a cause or a consequence or a mere marker necessitates further clarification. This review focuses on the pathophysiological aspects of homocysteines involvement in neurodegenerative and neuropsychiatric disorders and complications. The pharmacological agents (antiepileptic drugs, L-DOPA) augment the homocysteine levels, thus, raising concern for physicians. The mechanisms underlying the enhanced homocysteine levels and its related pathophysiological cascades remain poorly understood, inspite of numerous epidemiological and research studies that have been carried out in recent years. This article will review the current understanding of these underlying mechanisms and the research being carried with homocysteine as a core molecule.
Export Options
About this article
Cite this article as:
Khanna Suruchi, Kapoor Puneet, K. Pillai K. and Vohora Divya, Homocysteine in Neurological Disease: A Marker or a Cause?, CNS & Neurological Disorders - Drug Targets 2011; 10 (3) . https://dx.doi.org/10.2174/187152711794653797
DOI https://dx.doi.org/10.2174/187152711794653797 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Patents in Imaging of the Vulnerable Atherosclerotic Plaque: The Search for the Holy Grail
Recent Patents on Medical Imaging Perioperative Thromboprophylaxis and Anticoagulation in Patients Undergoing Non-Cardiac Vascular Surgery
Current Vascular Pharmacology Intradialytic Hypertension: An Under-recognized Cardiovascular Risk Factor. What is the Evidence?
Current Hypertension Reviews Microalbuminuria and the Hypertensive Disorders of Pregnancy
Current Hypertension Reviews Interventional Radiology in Paediatrics
Current Pediatric Reviews Role of Tyrosine Isomers in Acute and Chronic Diseases Leading to Oxidative Stress - A Review
Current Medicinal Chemistry Cardiovascular Effects of Phosphodiesterase 5 Inhibitors
Current Pharmaceutical Design Angiogenesis-regulating microRNAs and Ischemic Stroke
Current Vascular Pharmacology Plant Terpenes on Treating Cardiovascular and Metabolic Disease: A Review
Protein & Peptide Letters An Introduction to Obesity and Dementia
Current Alzheimer Research Classical to Current Approach for Treatment of Psoriasis: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Nitric Oxide-Mediated Endothelial Dysfunction - Is there Need to Treat?
Current Vascular Pharmacology Risk Stratification of Dyslipidemia: Insights from the Framingham Study
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Cardiac and Pulmonary Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Neuropathological Correlates of Cerebral Multimorbidity
Current Alzheimer Research Disturbance of Inorganic Phosphate Metabolism in Diabetes Mellitus: Its Impact on the Development of Diabetic Late Complications
Current Diabetes Reviews Editorial [Hot Topic: Trends in Vascular Biology; Functional Restoration of Damaged Endothelium (Executive Editors: J.A. Rodriguez-Feo and G. Pasterkamp)]
Current Pharmaceutical Design Platelets in Atherothrombosis: New and Evolving Roles
Current Pharmaceutical Design Pharmacological Inhibition of Poly(ADP-ribose) Polymerase in Cardiovascular Disorders: Future Directions
Current Vascular Pharmacology Pericyte: Potential Target for Hemorrhagic Stroke Prevention and Treatment
Current Drug Delivery